Biovault Technical

What Biovault Technical does

Biovault Technical Ltd is a UK private limited company headquartered in Plymouth that operates as a bioresource providing stem cell processing, tissue banking, and cellular therapy distribution services. Founded in 2002, the company operates from a purpose-built GMP-compliant facility adjacent to Derriford Teaching Hospital, featuring three independent Grade B cleanrooms, cryogenic vapour-phase storage at ≤-150°C, ultra-low temperature freezers, and a 21 CFR-compliant LIMS integrated with a Quality Management System. Biovault is the only stand-alone private JACIE-accredited processing facility in the UK, holding HTA Licence No. 11063, JACIE Accreditation No. 1015, and MHRA WDA(H) Licence No. 58837. The company has processed over 4,000 stem cell units for transplant since inception and processed 1,552 cellular therapy products in 2023 alone.

The company's revenue is generated through five interconnected service lines: cellular therapy processing (HPCs, CAR-T, T-cell products, bone marrow, cord blood), biobanking (ATMPs, DNA, tissues), allograft distribution (via partnerships with Int2Med and NCTB Europe), consultancy for biobank setup, and support services including cold chain logistics and LIMS/QMS. Pricing is project-based and quote-driven rather than publicly disclosed, with multi-year NHS contracts forming the revenue backbone. Biovault serves as the designated tissue bank for the NHS South West Peninsula Transplant Service and supports seven NHS trusts through long-term and contingency partnerships. International clients include Bio-Cord SLZ (Spain) and STEM Sure Romania. End users include haematologists, oncologists, transplant teams, orthopaedic surgeons, research institutions, and CROs.

Go-to-market is enterprise field sales with consultation-driven deal progression, complemented by content marketing via an active insights blog, thought leadership publications, and industry event presence at EBMT annual meetings. The company has selectively engineered proprietary cryoshipper and CRF rack systems (V1 and V2) to address gaps in standard cellular therapy logistics equipment. In June 2022 Biovault discontinued its consumer-facing Biovault Family private cord blood banking service, refocusing exclusively on B2B clinical and bioresource services, and in December 2024 it acquired the MHRA WDA(H) licence enabling direct CAR-T distribution to South West England hospitals.

Name

Biovault Technical

Legal name

Biovault Technical Ltd

Website

https://biovaulttechnical.co.uk

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Biovault Technical is a UK-based, JACIE-accredited bioresource providing stem cell processing, cryogenic biobanking, allograft distribution, and CAR-T therapy logistics to NHS trusts, hospitals, and international partners from its Plymouth GMP facility.

Ownership category

akta.pro rank

Product category

Cellular Therapy Processing & Biostorage Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

akta.pro secondary industries

Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)

Keywords

• Stem cell processing
• Tissue banking services
• Cellular therapy processing
• Biobanking storage services
• Allograft distribution

Headquarters

HQ city

Plymouth

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Cellular Therapy Processing Services: Processing, cryopreservation and storage of stem cells (PBSCs, bone marrow, cord blood), T-cell products, CAR-T therapies, and immune effector cells for clinical transplantation and research. Revenue is generated through per-product processing fees, with pricing likely project-specific given the highly regulated and customisable nature of services.
2. Biobanking and Storage Services: Secure storage of biological materials including ATMPs, tissues (tendons, bone products, skin), DNA, and research samples at cryogenic (-150°C+), ultra-low (-60°C to -80°C), cold chain (2°C to 8°C), and ambient temperatures. Storage fees are charged for long-term custody of biological assets.
3. Allograft Distribution: Import, storage, and distribution of allograft products (bone, tendon, ligament, meniscus, skin, ocular, cardiothoracic, DBM) to hospitals and surgeons through partnership with Int2Med and NCTB Europe. Revenue from product sales and distribution fees.
4. Consultancy Services: Bespoke consultancy for organisations establishing or optimising biobank or bioresource facilities, including regulatory compliance guidance, quality standards design, validation services, facility design, Designated Individual services, and contingency planning.
5. Support Services: Cold chain logistics with GDP-certified couriers, WDA(H) distribution services, data security and bioinformatics through LIMS systems, and NHS IG compliance services.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Biovault Technical is a UK-based JACIE-accredited stem cell and tissue bioresource that processes, cryopreserves, stores, and distributes cellular therapy products (including HPCs, CAR-T, PBSCs, DLIs, and IECs), allografts, and other biological materials for NHS trusts, hospitals, research organisations, and international partners. Operating from a purpose-built GMP-compliant facility in Plymouth, the company provides end-to-end cellular therapy processing, secure biobanking at cryogenic, ultra-low, and cold chain temperatures, allograft supply and distribution via partnerships with Int2Med and NCTB Europe, GDP-compliant cold chain logistics, and bespoke biobank consultancy under HTA, JACIE, MHRA WDA(H), GMP, and GDP regulatory frameworks.

Product overview

Biovault Technical operates as a bioresource offering a suite of integrated services centred on the processing, storage, and distribution of cellular products and human tissues. The core portfolio consists of six interconnected services: Cellular Therapy Processing (HPCs, T-cell products, CAR-T, PBSCs, DLIs, IECs), Biobanking (ATMPs, DNA, tissues), Allografts (bone, soft tissue, tendons, skin, ocular grafts), Support Services (LIMS, cold chain logistics, GDP/WDA(H) distribution), Consultancy (biobank setup and optimisation), and Contingency Planning & Business Continuity. Supporting add-on capabilities include CFU/gm testing services and proprietary engineered innovations such as enhanced cryoshipper racks and CRF freezer racks for cellular therapy logistics. A former consumer-facing offering, Biovault Family (private cord blood banking), was discontinued in June 2022. The entire portfolio is underpinned by HTA licensing, JACIE accreditation, and MHRA WDA(H) authorisation.

Differentiator

Problem solved

Functional benefit

Products and services

• Cellular Therapy Processing Processing, storage, and distribution of cellular products including haematopoietic progenitor cells (HPCs) from apheresis, marrow, and cord blood sources, T-cell products, CAR-T therapies, peripheral blood stem cells (PBSCs), donor lymphocyte infusions (DLIs), and immune effector cells (IECs) for clinical transplantation and research under HTA, JACIE, GDP, and MHRA WDA(H) accreditation.
• Biobanking Secure storage solutions for biological materials including advanced therapy medicinal products (ATMPs), DNA, tissues, and research and legal samples across cryogenic (≤-150°C), ultra-low (-60°C to -80°C), cold chain (2°C to 8°C), and ambient temperature regimes with continuous monitoring and full chain of custody.
• Allografts Supply, storage, and distribution of allograft products including bone, soft tissue, tendons, ligaments, menisci, skin, ocular, cardiothoracic, and maxillofacial allografts for surgical applications, provided through partnerships with Int2Med (since 2012) and NCTB Europe (since 2018) with bespoke sizing, patient-matched solutions, and return/restock policies.
• Support Services Data security and bioinformatics via a 21 CFR compliant Laboratory Information Management System (LIMS), GDP-certified cold chain logistics, NHS Information Governance compliance, and WDA(H) distribution services for biological materials across public and private sector organisations.
• Consultancy Bespoke consultancy services for organisations establishing or optimising biobank or bioresource facilities, covering regulatory compliance guidance (HTA, JACIE, MHRA), quality standards design, facility design, validation services, Designated Individual services, and contingency planning.
• Contingency Planning & Business Continuity Services to protect biological assets and ensure seamless operational continuity for universities, hospitals, and trusts, including 24/7 monitoring, redundant power and gas supplies, customisable cleanroom facilities, and emergency processing support during planned or unplanned service disruptions.

Quantifiable outcome

• 11.3% emissions reduction in first year of Net Zero pledge through energy efficiency measures (electricity -10.5%, gas -11.1%, dry ice losses -23.1%)
• +3 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• NCTB EuropecoreChannel Partner/ Reseller/ Distributor · 1 January 2018Partnership since 2018 with NCTB Europe, a leading medical tissue facility, to supply fully tested allografts meeting UK HTA standards. NCTB provides chemically sterilised (non-irradiated) allografts including tendons, large osteochondral grafts, meniscus allografts, ocular and amniotic allografts, and demineralized bone matrix products.
• STEM Sure RomaniaminorStrategic or Co-development Partner · 1 January 2015Partnership since 2015 for processing and storage of stem cell samples from Romania. Thousands of samples have been transferred safely from Romania to the UK for processing and storage, with some returned to Romania for transplantation. Brexit was navigated seamlessly with all statutory licences and processes maintained.
• Bio-Cord SLZminorStrategic or Co-development Partner · 1 January 2013European partnership since 2013 for processing and storage of umbilical cord stem cells from the Spanish market. Bio-Cord searched for a processing and storage facility in Europe and found Biovault's Plymouth facility 'truly excellent' with high capacity and quality service at competitive pricing.
• Int2MedcoreStrategic or Co-development Partner · 1 January 2012Long-established collaboration since 2012 for allograft product supply and distribution. Int2Med provides guidance and support in the highly regulated human tissue supply system in the UK while depending on Biovault's technical knowledge, regulatory understanding, and storage facilities for physical product handling.
• NHS South West Peninsula Transplant ServicecoreStrategic or Co-development PartnerBiovault has been the designated tissue bank for the NHS South West Peninsula Transplant Service since 2006, providing critical stem cell storage and tissue processing solutions. This is Biovault's primary public sector partnership and forms the foundation of their NHS work.
• Anthony NolancoreStrategic or Co-development PartnerBiovault processes donations from Anthony Nolan's international registry network of stem cell donors. In 2023, Biovault processed 41 donations from Anthony Nolan, matching remarkable stem cell donors to people in need of lifesaving transplants.
• Plymouth Health Innovation AlliancecoreStrategic or Co-development PartnerFounding member of the Plymouth Health Innovation Alliance driving regional and global health innovations. Collaborative projects include research on microplastic accumulation in humans with University Hospitals Plymouth.
• University Hospitals PlymouthcoreStrategic or Co-development PartnerCollaborative research partnership for microplastic accumulation studies. Biovault facility is located adjacent to Derriford Teaching Hospital, enabling close operational integration and CAR-T therapy delivery for South West patients.
• UK NHS Trusts (7 total)coreStrategic or Co-development PartnerBiovault supports seven UK NHS Trusts with both long-term and contingency solutions for stem cell processing and tissue banking. Depth and breadth of experience enables seamless service within ongoing or contingency partnerships.
• Contract Research Organisations (CROs)minorStrategic or Co-development PartnerPartnerships with CROs for blood fractionation services for both clinical and research applications, providing flexible and cost-effective solutions for cellular therapy development.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Lonza Cell & Gene Technologies: Global CDMO offering cell and gene therapy manufacturing including autologous and allogeneic cell therapies. Comparable GMP cellular processing capabilities but operating globally across many cell therapy modalities rather than UK regional focus.
• NHS Blood and Transplant (NHSBT): UK public-sector provider of cellular therapy and stem cell processing services, including cord blood banking. Direct overlap with Biovault's NHS processing and storage activities but operating at national scale rather than regional niche.

Direct peers

• Cryoport Systems: Specialised cold chain logistics provider for cell therapies, regenerative medicine, and reproductive materials. Overlap with Biovault's cryoshipper/cryogenic logistics and CAR-T distribution services, with comparable proprietary cold-chain rack innovations.
• BioLife Solutions: Supplier of cryopreservation media, storage equipment, and cold-chain tools for cell and gene therapies. Adjacent to Biovault's biobanking and cryogenic processing services; both serve cell therapy logistics workflows with proprietary cryogenic technology.
• RoslinCT: Scotland-based cell therapy CDMO offering GMP manufacturing for cell and gene therapies including CAR-T. Comparable cell therapy processing services and similar regulatory positioning (MHRA, HTA, JACIE-equivalent) to Biovault, but at significantly larger scale.
• Anthony Nolan Cell Therapy Centre: Existing customer (41 donations processed in 2023) that also operates its own cellular therapy and stem cell processing infrastructure. Closest functional peer given the relationship overlap, though primarily a registry versus a service provider.
• Future Cell Therapy (Manchester): UK-based GMP-compliant cell therapy manufacturing facility providing processing and storage for NHS and academic cell therapy programs. Comparable UK cellular processing service offering competing for similar NHS stem cell processing contracts.

Regional players

• Cell and Gene Therapy Catapult: UK government's cell and gene therapy accelerator offering manufacturing, process development, and clinical trial support. Comparable regulatory expertise in HTA/MHRA and adjacent cell therapy positioning, though operating as a non-profit development catalyst rather than a commercial processor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/biovault-ltd
• Xx.com/BiovaultTech

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biovault Technical